Albers Jeffrey W. — SEC Form 4 filings
SEC reporting owner CIK 1638474. 29 Form 4 filings on record with FilingPulse; latest filed 2026-08-10.
Transaction summary — filings shown
Covers all 29 filings on record, filed 2024-01-23 to 2026-08-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 39 legs across 20 filings — 205,584 shares, $17,085,817 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 57.
- Largest priced transaction: sale of 10,000 shares @ $104.68 ($1,046,800) in Spyre Therapeutics, Inc., filed 2026-08-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Blueprint Medicines Corp (BPMC) | Director | 14 | — | 26 legs · 139,235 sh · $12,627,276 | 35 |
| Spyre Therapeutics, Inc. (SYRE) | Director | 6 | — | 5 legs · 30,000 sh · $2,661,432 | 5 |
| Kymera Therapeutics, Inc. (KYMR) | Director | 9 | — | 8 legs · 36,349 sh · $1,797,109 | 17 |
Form 4 filings — Albers Jeffrey W.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-10 | 4 | Spyre Therapeutics, Inc. (SYRE) | Option exercise (M): 5,000 @ $10.39 · Sale (S): 5,000 @ $104.47 · Sale (S): 8,000 @ $104.38 · Sale (S): 10,000 @ $104.68 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Kymera Therapeutics, Inc. (KYMR) | Grant/award (A): 6,068 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 8,026 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | Kymera Therapeutics, Inc. (KYMR) | Option exercise (M): 5,000 @ $14.18 · Sale (S): 2,748 @ $89.32 · Sale (S): 2,252 @ $90.30 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-10-14 | 4 | Kymera Therapeutics, Inc. (KYMR) | Option exercise (M): 5,000 @ $10.34 · Sale (S): 5,000 @ $59.19 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-07-21 | 4 | Blueprint Medicines Corp (BPMC) | Disposition to issuer (D): 5,777 · Code (U): 144,755 · Disposition to issuer (D): 92,500 (derivative) · Disposition to issuer (D): 170,000 (derivative) · Disposition to issuer (D): 110,500 (derivative) · Disposition to issuer (D): 90,000 (derivative) · +4 more | EDGAR |
| 2025-06-26 | 4 | Kymera Therapeutics, Inc. (KYMR) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Blueprint Medicines Corp (BPMC) | Grant/award (A): 3,902 @ $128.12 | EDGAR |
| 2025-06-03 | 4 | Kymera Therapeutics, Inc. (KYMR) | Option exercise (M): 6,349 @ $10.34 · Sale (S): 6,349 @ $49 · Option exercise (M): 6,349 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-05-29 | 4 | Blueprint Medicines Corp (BPMC) | Option exercise (M): 5,000 @ $36.05 · Sale (S): 4,350 @ $101.02 · Sale (S): 650 @ $101.93 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | Blueprint Medicines Corp (BPMC) | Sale (S): 5,766 @ $88.80 | EDGAR |
| 2025-03-14 | 4 | Blueprint Medicines Corp (BPMC) | Option exercise (M): 7,500 @ $36.05 · Sale (S): 5,700 @ $87.62 · Sale (S): 1,800 @ $88.37 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Blueprint Medicines Corp (BPMC) | Option exercise (M): 10,000 @ $36.05 · Sale (S): 7,561 @ $109.11 · Sale (S): 7,400 @ $109.92 · Sale (S): 200 @ $110.61 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-01-15 | 4 | Blueprint Medicines Corp (BPMC) | Option exercise (M): 5,000 @ $36.05 · Sale (S): 5,000 @ $102.28 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-12-20 | 4 | Blueprint Medicines Corp (BPMC) | Option exercise (M): 15,000 @ $36.05 · Sale (S): 3,920 @ $88.28 · Sale (S): 5,180 @ $89.01 · Sale (S): 3,800 @ $91.15 · Sale (S): 2,100 @ $91.96 · Option exercise (M): 15,000 (derivative) @ $36.05 | EDGAR |
| 2024-11-12 | 4 | Blueprint Medicines Corp (BPMC) | Option exercise (M): 5,000 @ $36.05 · Sale (S): 5,000 @ $102 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 6,700 @ $36.76 | EDGAR |
| 2024-10-28 | 4 | Spyre Therapeutics, Inc. (SYRE) | Sale (S): 300 @ $36.43 | EDGAR |
| 2024-09-11 | 4 | Blueprint Medicines Corp (BPMC) | Option exercise (M): 10,000 @ $36.05 · Sale (S): 11,968 @ $85.86 · Sale (S): 7,734 @ $85.12 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-08-26 | 4 | Kymera Therapeutics, Inc. (KYMR) | Option exercise (M): 5,000 @ $10.34 · Sale (S): 5,000 @ $49.10 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Kymera Therapeutics, Inc. (KYMR) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Blueprint Medicines Corp (BPMC) | Grant/award (A): 2,242 @ $0 · Grant/award (A): 4,570 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 11,323 (derivative) @ $0 | EDGAR |
| 2024-03-26 | 4 | Blueprint Medicines Corp (BPMC) | Sale (S): 11,033 @ $90.69 | EDGAR |
| 2024-03-22 | 4 | Blueprint Medicines Corp (BPMC) | Option exercise (M): 15,073 @ $1.87 · Option exercise (M): 10,000 @ $15.01 · Sale (S): 2,730 @ $85.22 · Sale (S): 6,251 @ $86.46 · Sale (S): 8,440 @ $87.26 · Sale (S): 6,285 @ $88.60 · +3 more | EDGAR |
| 2024-02-21 | 4 | Kymera Therapeutics, Inc. (KYMR) | Option exercise (M): 615 @ $10.34 · Sale (S): 615 @ $39.07 · Option exercise (M): 4,385 @ $10.34 · Sale (S): 4,385 @ $39.05 · Option exercise (M): 615 (derivative) @ $0 · Option exercise (M): 4,385 (derivative) @ $0 | EDGAR |
| 2024-01-29 | 4 | Blueprint Medicines Corp (BPMC) | Option exercise (M): 15,000 @ $1.87 · Option exercise (M): 10,000 @ $15.01 · Sale (S): 6,086 @ $81.16 · Sale (S): 10,890 @ $81.70 · Sale (S): 7,924 @ $82.76 · Sale (S): 100 @ $83.57 · +2 more | EDGAR |
| 2024-01-23 | 4 | Kymera Therapeutics, Inc. (KYMR) | Option exercise (M): 10,000 @ $10.34 · Sale (S): 10,000 @ $30.05 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1638474 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →